Recombinant Human CD59 Protein (Leu26-Asn102), GST tagged

• Cat.No.: CD59-0955H
• Product Overview: Recombinant human CD59 (Leu26-Asn102) fused with GST tag was expressed in E. coli.

Specification

• Description: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
• Source: E. coli
• Species: Human
• Tag: GST
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 34.83 kDa
• Protein length: Leu26-Asn102
• Purity: >90% as determined by SDS-PAGE.
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles.
  Store at 2 to 8 centigrade for one week.
  Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: Supplied as solution form in PBS pH 7.5 or lyophilized from PBS pH 7.5.
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: CD59 CD59 molecule, complement regulatory protein [ Homo sapiens (human) ]
• Official Symbol: CD59
• Synonyms: CD59; CD59 molecule, complement regulatory protein; CD59 antigen p18 20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344), CD59 antigen, complement regulatory protein, MIC11, MIN1, MIN2, MIN3, MSK21; CD59 glycoprotein; 16.3A5; EJ16; EJ30; EL32; G344; p18 20; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); 1F5; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; HRF-20; MAC-IP; p18-20; MGC2354; FLJ38134; FLJ92039
• Gene ID: 966
• mRNA Refseq: NM_000611
• Protein Refseq: NP_000602
• MIM: 107271
• UniProt ID: P13987

Reviews

05/09/2022

The quality is very high and the reliability is very helpful for our research results.

03/17/2021

There are no doping impurities, the experimental effect is very good, and I will recommend it to other students.

01/13/2021

Easy to operate and cost-effective.

Q&As

How to explain the role of CD59 in hemolytic disease?

In hemolytic diseases, the deficiency or dysfunction of CD59 may lead to excessive lysis of red blood cells because the formation of the complement C5b-9 complex cannot be effectively prevented.

Are there differences in CD59 expression levels in different types of cells?

Yes, the expression level of CD59 can vary in different cell types. In general, it is expressed higher in blood cells and some tumor cells.

What are some of the technical challenges that laboratories may encounter when researching CD59?

When researching CD59, laboratories may encounter technical challenges such as selecting the appropriate assay, ensuring the quality and consistency of samples, and the complexity of interpreting results. In addition, CD59 expression variations in different cell types and experimental conditions need to be considered.

What diseases are associated with aberrant expression of CD59?

Aberrant expression of CD59 has been associated with a variety of diseases, including but not limited to hemolytic diseases, certain types of cancer, and autoimmune diseases.

How can I measure CD59 expression in the laboratory?

CD59 expression can be detected using flow cytometry, immunofluorescence staining, or western blotting.

Is there a current treatment for CD59?

The current treatment for CD59 is still in the research stage, and there is no drug approved for clinical use. However, some studies are exploring the use of gene therapy or antibody therapy to modulate CD59 expression or function.